ライフサイエンスコーパス: VMAT

1 VMAT seemed to be the optimal technique for NSCLC.

2 VMAT transport is inhibited by the competitive inhibitor

3 rain, the vesicular monoamine transporter-2 (VMAT(2)) is responsible for the loading of dopamine (DA)

4 , DAT and vesicular monoamine transporter-2 (VMAT) in the striatum, medial forebrain bundle and the v

5 ng of the vesicular monoamine transporter-2 (VMAT-2) ligand dihydrotetrabenazine (DHTBZ) in a dose- a

6 Vesicular monoamine transporter-2 (VMAT-2) plays a critical role in dopamine storage by pac

7 Because reserpine (a VMAT inhibitor) can precipitate depressive-like symptoms

8 omatic L-amino acid decarboxylase (AADC) and VMAT-2 genes.

9 ines must be actively transported by DAT and VMAT in tandem to produce psychostimulant effects.

10 HT and VMAT plans generated essentially equivalent PTV coverage

11 nt striatal neuronal loss, despite TH-IR and VMAT-IR reduction in a subset of animals, supporting the

12 fic differences in the expression of NET and VMAT-1 do not translate into differences in (123)I-MIBG

13 VAChT and VMAT exchange two protons per substrate molecule with ve

14 VAChT and VMAT exhibit partial structural and mechanistic homology

15 Comparative analysis of the VAChT and VMAT transport mechanisms will aid understanding of regu

16 s, HT was found to be superior to 2 or 8-arc VMAT for optimal OAR sparing (meeting all the dose const

17 onduct a study to compare HT and partial-arc VMAT in their ability to spare organs at risk (OARs) whe

18 The MPD-induced increase in both VMAT-2 immunoreactivity and DHTBZ binding was attenuated

19 Interestingly, the Vmax of both VMATs for dopamine exceeded that for serotonin by 3-5-fo

20 This release was accompanied by VMAT-mediated serotonin depletion from the nucleus, a la

21 nction and results from net H(+) antiport by VMAT out of the vesicle lumen coupled to inward amphetam

22 consequence of the H(+) countertransport by VMAT that accompanies vesicular uptake, but not by induc

23 Hence, somatic vesicles loaded by VMAT during activity rapidly undergo exocytosis.

24 ms of the present study were to characterize VMAT representatives in rat gastric corpus, and to deter

25 res of MPP(+) and a previously characterized VMAT inhibitor, 3-amino-2-phenyl-propene, have been iden

26 monoamine transporter (VMAT), and a charged VMAT, substrate 1-methyl-4-phenylpyridinium (MPP(+)), re

27 During the transport cycle, VMAT is expected to occupy at least three different conf

28 ition, MPD treatment increased and decreased VMAT-2 immunoreactivity in striatal vesicle subcellular

29 rodegeneration, whereas mutations decreasing VMAT and tyrosine hydroxylase exacerbated toxicity.

30 We used the Drosophila VMAT (dVMAT) null mutant to globally ablate exocytotic a

31 ort characteristics and pharmacology of each VMAT isoform have been directly compared after expressio

32 , have been identified as the most effective VMAT inhibitors.

33 tant phenotypes can be rescued by C. elegans VMAT constructs and also (at least partially) by human V

34 The C. elegans VMAT gene is cat-1; cat-1 knock-outs are totally deficie

35 C. elegans VMAT is associated with synaptic vesicles in approximate

36 The pharmacological profile of C. elegans VMAT is closer to mammalian VMAT2 than VMAT1.

37 When C. elegans VMAT is expressed in mammalian cells, it has serotonin a

38 energy gradient for amine-proton exchangers (VMATs) to concentrate small transmitter molecules, for e

39 ; cat-1 knock-outs are totally deficient for VMAT immunostaining and for dopamine-mediated sensory be

40 Results of use of methodology for VMAT commissioning and quality assurance, utilizing both

41 ine receptor 1, dopamine transporters or for VMAT.

42 rection respectively with better results for VMAT (0.4%) vs. IMRT (1.6%) plans.

43 al elements, including the aminoethyl group (VMAT recognition), halogenated hydroxy-coumarin core (ra

44 embrane dopamine transporter (DAT) and human VMAT ortholog, VMAT2.

45 Overall, we identify VMAT as an important regulator of sleep in Drosophila an

46 Compared to TOMO and IMRT, VMAT achieved better target dose distribution and simila

47 such cases, increasing the number of arcs in VMAT cannot significantly improve OAR sparing.

48 gnificantly superior mean CI was observed in VMAT than in TOMO or IMRT (P = 0.013, 0.001).

49 ion of the aromatic ring gradually increases VMAT inhibition potency from 4'-F to 4'-I, parallel to t

50 of multiple metastases with single-isocenter VMAT.

51 Mean VMAT-1 expression in hereditary cluster 1 PPGLs was sign

52 results show that some CYAM is in DA neuron VMAT vesicles and suggests a new drug interaction in whi

53 urther identified three cytosolic domains of VMAT(2) involved in the interaction with TH and AADC.

54 pine sensitivity, suggesting that effects of VMAT/reserpine on sleep are mediated by multiple monoami

55 and, because of its selective inhibition of VMAT-2, it preferentially depletes dopamine (DA).

56 ISC was strongly attenuated by inhibitors of VMAT (reserpine and tetrabenazine) and DAT (GBR12909 and

57 for DA in the MPD-induced redistribution of VMAT-2.

58 ggest possible differences in the sorting of VMATs versus VGLUTs to SVs at the synapse.

59 owever, did not correlate with either NET or VMAT-1 expression.

60 osely related VMAT(1) and with overexpressed VMAT(2).

61 -immunoprecipitates with the closely related VMAT(1) and with overexpressed VMAT(2).

62 amphetamine-induced deacidification requires VMAT function and results from net H(+) antiport by VMAT

63 of altanserin (5HTR2 inhibitor), reserpine (VMAT inhibitor), and VP16-XlCreb1 (constitutively active

64 To study VMAT's role in mediating amphetamine action in dopamine

65 We conclude that VMAT expression confers the linked abilities to store bi

66 There is evidence that VMAT activity modulates prohormone cleavage, but in the

67 Here, we provide evidence that VMAT(2) physically and functionally interacts with the e

68 -relevant target of reserpine, we found that VMAT-null mutants have an increased sleep phenotype, as

69 Supporting the idea that VMAT is the sleep-relevant target of reserpine, we found

70 However, although the VMAT mutants are consistently resistant to reserpine, ot

71 VMAT2; the latter was reduced to 5.8 by the VMAT inhibitor reserpine.

72 in the presence of fragments involved in the VMAT(2)/TH/AADC interaction.

73 to define the structural requirements of the VMAT substrate and inhibitor activities.

74 modeled in rodents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibito

75 rimers to DNA sequences conserved within the VMAT family provided evidence for VMAT2, but not VMAT1 i

76 VAChT and the VMATs contain COOH-terminal, cytoplasmic dileucine motif

77 zes to the same endosomal compartment as the VMATs by immunofluorescence, density gradient fractionat

78 Conversely, the VMATs contain two glutamates upstream of their dileucine

79 In PC12 cells, VAChT differs from the VMATs by immunofluorescence and fractionates almost excl

80 mary, VAChT differs in localization from the VMATs in PC12 cells but not CHO cells.

81 Thus, VAChT differs in localization from the VMATs, which sort predominantly to LDCVs.

82 have investigated the phosphorylation of the VMATs.

83 nteract through distinct mechanisms with the VMATs and that the recognition of each ligand involves m

84 y (HT) and volumetric modulated arc therapy (VMAT) are both advanced techniques of delivering intensi

85 -isocenter volumetric modulated arc therapy (VMAT) has been shown to decrease treatment time with the

86 py (TOMO), volumetric-modulated arc therapy (VMAT), and fixed-field intensity-modulated radiotherapy

87 vesicular pH due to proton transport through VMATs.

88 it is physically and functionally coupled to VMAT(2)-mediated transport into vesicles.

89 HT appears to be superior to VMAT in OAR sparing mainly in cases which require confor

90 ffects of the vesicular monoamine transport (VMAT) inhibitor tetrabenazine.

91 ffects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine (TBZ) were investigated.

92 tion of the vesicular monoamine transporter (VMAT) blocks amphetamine-induced locomotion and self-adm

93 ment of the vesicular monoamine transporter (VMAT) for the vesicular storage and exocytotic release o

94 ging by the vesicular monoamine transporter (VMAT) is essential for mood-controlling serotonin transm

95 sion of the vesicular monoamine transporter (VMAT) rescued the dopamine toxicity and neurodegeneratio

96 that act as vesicular monoamine transporter (VMAT) substrates and ratiometric fluorescent pH sensors.

97 fin granule vesicular monoamine transporter (VMAT) that have been previously characterized as potent

98 itor of the vesicular monoamine transporter (VMAT) that repackages monoamines into presynaptic vesicl

99 (VAChT) and vesicular monoamine transporter (VMAT) transport neurotransmitter substrates into secreto

100 Vesicular monoamine transporter (VMAT), a member of the largest superfamily of transporte

101 acting via vesicular monoamine transporter (VMAT), and a charged VMAT, substrate 1-methyl-4-phenylpy

102 ERT and the vesicular monoamine transporter (VMAT), we have identified a role for ongoing 5-HT releas

103 DAT) or the vesicular monoamine transporter (VMAT).

104 tes for the vesicular monoamine transporter (VMAT).

105 ting of the vesicular monoamine transporter (VMAT).

106 vity of the vesicular monoamine transporter (VMAT)2.

107 r (NET) and vesicular monoamine transporter (VMAT-1) was evaluated immunohistochemically in paraffin-

108 ly related vesicular monoamine transporters (VMATs) 1 and 2 differ substantially in ligand recognitio

109 The vesicular monoamine transporters (VMATs) 1 and 2 show close sequence similarity but substa

110 ies of the vesicular monoamine transporters (VMATs) indicate preferential localization to large dense

111 ly related vesicular monoamine transporters (VMATs) localize preferentially to large dense core vesic

112 The vesicular monoamine transporters (VMATs) package monoamine neurotransmitters into secretor

113 Vesicular monoamine transporters (VMATs) translocate monoamines from the cytoplasm into se

114 tified two vesicular monoamine transporters (VMATs), one expressed in non-neural cells of the periphe

115 mammalian vesicular monoamine transporters (VMATs); it is 47% identical to human VMAT1 and 49% ident

116 In larger tumor, VMAT provided the optimal dose distribution and sparing

117 iological rationale for the existence of two VMATs.

118 anism for differential regulation of the two VMATs.

119 Agreement in the static vs. VMAT picket fence control point test was better than 0.5

120 Increasing the number of arcs with VMAT also led to some improvement in OAR sparing.

121 demonstrate that TH and AADC associate with VMAT(2)-containing synaptic vesicles from rat brain.

122 riata, TH and AADC co-immunoprecipitate with VMAT(2), whereas in PC 12 cells, TH co-immunoprecipitate

123 demonstrated that TH directly interacts with VMAT(2).

124 ncreasing from 2 to 8 arcs was observed with VMAT.